Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX has been on the market in many countries outside the United States and has been used in more than 340,000 patients to date. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It is also continuing its legacy business of manufacturing and selling certain reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.